Merck & Co., Inc. (LON: 0QAH)

Market Cap	197.61B
Revenue (ttm)	47.13B
Net Income (ttm)	9.06B
Shares Out	n/a
EPS (ttm)	3.57
PE Ratio	21.80
Forward PE	n/a
Dividend	2.43 (2.71%)
Ex-Dividend Date	Dec 16, 2024

Volume	2,180
Average Volume	35,016
Open	89.29
Previous Close	89.70
Day's Range	89.29 - 95.07
52-Week Range	84.53 - 119.56
Beta	0.41
RSI	32.70
Earnings Date	Feb 4, 2025

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M−M−R II, Variv...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1891
• Employees: 72,000
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QAH

Financial Performance

In 2023, Merck & Co.'s revenue was $60.12 billion, an increase of 1.40% compared to the previous year's $59.28 billion. Earnings were $365.00 million, a decrease of -97.49%.

Financial numbers in USD